SHBG: The Overlooked Biomarker That Predicts Diabetes and Heart Disease

Sex hormone-binding globulin does not get the attention it deserves. Most patients have never heard of it, and many providers check it only as an afterthought when testosterone or estrogen levels seem inconsistent with symptoms. But SHBG is emerging as one of the most powerful independent predictors of metabolic and cardiovascular disease we have. A population-based study published in the Journal of Clinical Endocrinology & Metabolism found that SHBG levels directly and indirectly predict coronary heart disease risk in both men and women.

The metabolic connection is striking. Low SHBG is independently associated with metabolic syndrome and serves as a strong predictor of type 2 diabetes risk. Men in the highest quartile of SHBG levels had an odds ratio of 0.10 for diabetes compared to the lowest quartile, meaning tenfold lower risk. SHBG is inversely correlated with insulin resistance, and this relationship holds even after adjusting for BMI, age, and other metabolic markers.

Age-related changes in SHBG follow distinct trajectories by sex. In men, SHBG increases steadily from the mid-40s onward, driven by increased hepatic synthesis through changes in liver transcription factors. In women, SHBG follows a U-shaped curve, declining through the reproductive years and rising again after the sixth decade. These age-related changes directly affect the bioavailability of testosterone and estrogen, meaning that total hormone levels become less clinically meaningful without knowing SHBG.

A man with "normal" total testosterone but elevated SHBG may actually have clinically low free testosterone. Conversely, a man with borderline-low total testosterone but very low SHBG may have adequate free testosterone. Without SHBG, the clinical picture is incomplete.

The Tracking Connection

Kairos™ tracks SHBG as a core biomarker alongside total and free testosterone, estradiol, and metabolic indicators. By monitoring SHBG trends over time, Kairos helps users and providers interpret hormonal changes in their proper context, catching metabolic risk signals that hormone levels alone would miss and ensuring that treatment decisions are based on bioavailable hormone levels, not just total counts.